Although the alpha-specific PI3Ki alpelisib has recently been shown to significantly improve PFS in PIK3CA-mutated ER+ advanced breast cancer that progressed on previous endocrine therapy, this PI3Ki is not active in PIK3CA wild-type and PTEN null tumors17. Here, PIK3CA is linked to breast carcinoma.